Global X U.S. Infrastructure Development ETF PAVE 深 滬
已收盤 10-10 16:00:00 美东时间
46.42
-1.220
-2.56%
華盛通- 最 高48.00
- 今 開47.81
- 成交量 110.97万股
- 最 低 46.38
- 昨 收 47.64
- 總市值 91.91亿
- 52周最高 48.421
- 市盈率 靜 --
- 換手率 0.56%
- 52周最低 32.5397
- 委 比 -1.05%
- 總股本 1.98亿
- 歷史最高 48.421
- 量 比 1.60
- 振 幅 3.40%
- 歷史最低 8.7502
- 每 手 1
- 風險率 3.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多2025 洛杉矶车展 AUTOMOBILITY LA 登场，汇聚定义未来移动的产业领袖
Cox Automotive 荣誉呈献主舞台：Honda x LA28、Lucid、Pivotal、 ARC Boats 及 PAVE 等重量级嘉宾将分享前...
09-30 00:51
美银重磅报告：AI “卖水人”正在胜出！全球资金下一步可能流向哪里？
美银最新预测显示，受 8 月疲软非农数据影响，美联储今年可能降息 2 次，2026 年再降 3 次，最终利率将降至 3.25% 左右。
09-11 23:15
美银重磅报告：AI “卖水人”正在胜出！全球资金下一步可能流向哪里？
美银最新预测显示，受 8 月疲软非农数据影响，美联储今年可能降息 2 次，2026 年再降 3 次，最终利率将降至 3.25% 左右。
09-11 21:57
Housing Pains? Some ETFs Can Still Build Gains
U.S. construction spending slipped in July, but ETFs reveal a split: homebuilder funds face mortgage headwinds, while infrastructure ETFs may benefit.
09-03 03:42
Where to find high momentum showing a ‘bullish top-down signal’ – Oppenheimer
Oppenheimer analysts believe that the recent underperformance of the momentum factor (NYSEARCA:SPMO), (MTUM) through the broadening of the market is a “bullish top-down signal.” “We see this tactical ...
09-03 01:42
Reported Earlier, Apellis Wins FDA Approval For EMPAVELI To Treat Rare Kidney Diseases C3G And IC-MPGN With 68% Proteinuria Reduction
Proven efficacy across all three key markers of disease—68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 depositsBroad label includes adults and adolescents with C3G or
07-29 15:32
大摩上调Apellis Pharmaceuticals(APLS.US)目标价至26美元 维持“持有”评级
摩根士丹利分析师Judah Frommer表示，这一评级是基于该公司市场地位及近期财务战略所作出的判断。
07-07 11:58
Bowman Consulting Expands Into AI-Driven Data Center Engineering
Bowman Consulting Group Ltd. (NASDAQ: BWMN) acquires e3i Engineers for $2 million, expanding its expertise in data center and energy system design.
07-02 21:00
Apellis Pharmaceuticals Announced A Capped Royalty Purchase Agreement With Sobi Under Which Apellis Will Receive Up To $300M In Exchange For 90% Of Apellis' Future Ex-U.S. Royalties For Aspaveli (Systemic Pegcetacoplan)
Under the companies' 2020 collaboration agreement, Apellis is eligible for tiered royalties on ex-U.S. sales of Aspaveli ranging from high teens to high twenties. Apellis retains exclusive commercialization rights for
07-01 19:09
EXCLUSIVE: Ford, GM Just Hit A Tariff Wall - Will Margins Crumple On Cost Pressures?
Detroit automakers' stocks tumbled after 50% tariffs were announced on imported steel and aluminum, adding up to $400 to vehicle production costs.
06-05 22:19
